Literature DB >> 26969123

Return to Play After Periacetabular Osteotomy for Treatment of Acetabular Dysplasia in Adolescent and Young Adult Athletes.

Benton E Heyworth1, Eduardo N Novais2, Kerri Murray2, Gregory Cvetanovich3, David Zurakowski4, Michael B Millis2, Young-Jo Kim2.   

Abstract

BACKGROUND: The Bernese periacetabular osteotomy (PAO) is an effective surgical treatment option for symptomatic acetabular dysplasia. Little evidence exists regarding the results of PAO and rates of return to play (RTP) in an athletic population. HYPOTHESIS: The majority of athletes will demonstrate improvements in functional outcome measures, such as the modified Harris Hip Score and Hip Disability and Osteoarthritis Outcome Score, and will be able to return to sports after PAO. STUDY
DESIGN: Case series; Level of evidence, 4.
METHODS: A comprehensive surgical hip database at an academic referral center was used to identify a subpopulation of athletes on whom PAO was performed. Data analyzed included preceding surgeries, reoperations, and RTP timing and features. Standard pre- and postoperative radiologic parameters and validated functional outcome measures were assessed, and a regression model assessed risk factors for prolonged time to RTP.
RESULTS: Of 245 PAOs performed over the 5-year study period, 46 were performed in 41 patients who met inclusion criteria for being an athlete (mean age, 26.2 years; range, 13-41 years; 36 females; 19% of all PAOs), representing a variety of sports. Prior surgery had been performed on 9 hips (20%). Only 1 post-PAO procedure (2%), excision of heterotopic ossification, was performed during the study period. At final follow-up (median, 3.1 years; range, 1.2-4.4 years), significant mean improvements were observed in modified Harris Hip Score (from 71 to 90; P < .001) and Hip Disability and Osteoarthritis Outcome Score (from 64 to 89; P < .001). The University of California-Los Angeles Activity Scale scores were maintained at a high level (range, 8.0-8.2; P = .28). RTP was reported in 80% of patients (37 of 46) at a median of 9 months postoperatively, with increased postoperative pain as the only independent predictor of longer time to RTP. Of these 37 athletes, 27 (73%) returned to the same level, although this was significantly less common (P = .06) in competitive athletes (11 of 19; 58%) than in recreational athletes (16 of 18; 89%). Among those who did return at the same level, 23 of 27 (85%) were able to maintain this level over time, but this was not significantly different between competitive (8 of 11; 73%) and recreational (15 of 16; 94%) athletes (P = .27).
CONCLUSION: Most athletic patients undergoing PAO are female patients and show postoperative improvements in function and return to athletic play. However, although there was no decline in overall activity level at a mean of 3 years, self-assessed athletic performance was attained and maintained in approximately one-half of the study population.
© 2016 The Author(s).

Entities:  

Keywords:  Bernese periacetabular osteotomy; acetabular dysplasia; athletes; developmental dysplasia of the hip

Mesh:

Year:  2016        PMID: 26969123     DOI: 10.1177/0363546516632743

Source DB:  PubMed          Journal:  Am J Sports Med        ISSN: 0363-5465            Impact factor:   6.202


  13 in total

Review 1.  Hip dysplasia in the young adult caused by residual childhood and adolescent-onset dysplasia.

Authors:  Stephanie Pun
Journal:  Curr Rev Musculoskelet Med       Date:  2016-12

2.  Hip dysplasia in wrestlers: three lessons learned.

Authors:  J W Thomas Byrd; John C Clohisy; Young-Jo Kim; F Winston Gwathmey; Kay S Jones; Michael B Millis
Journal:  J Hip Preserv Surg       Date:  2017-08-02

3.  Do young female dancers improve symptoms and return to dancing after periacetabular osteotomy for the treatment of symptomatic hip dysplasia?

Authors:  Eduardo N Novais; Songkiat Thanacharoenpanich; Ali Seker; Matthew J Boyle; Patricia E Miller; Garrett Bowen; Michael B Millis; Young-Jo Kim
Journal:  J Hip Preserv Surg       Date:  2018-03-15

4.  Periacetabular osteotomy to treat residual dysplasia in adolescents and young adults: indications, complications, results.

Authors:  M B Millis; M McClincy
Journal:  J Child Orthop       Date:  2018-08-01       Impact factor: 1.548

5.  Are changes in pain associated with changes in quality of life and hip function 2 years after periacetabular osteotomy? A follow-up study of 321 patients.

Authors:  Julie Boje; Christina Krogner Caspersen; Stig Storgaard Jakobsen; Kjeld Søballe; Inger Mechlenburg
Journal:  J Hip Preserv Surg       Date:  2019-03-14

6.  Rate of Surgery and Baseline Characteristics Associated With Surgery Progression in Young Athletes With Prearthritic Hip Disorders.

Authors:  Reid W Collis; Andrea B McCullough; Chris Ng; Heidi Prather; Graham A Colditz; John C Clohisy; Abby L Cheng
Journal:  Orthop J Sports Med       Date:  2020-11-24

7.  Endoscopic Shelf Acetabuloplasty Concomitant With Labral Repair, Cam Osteoplasty, and Capsular Plication to Treat Acetabular Dysplasia in Artistic Athletes: A Case Series.

Authors:  Soshi Uchida; Yoichi Murata; Manabu Tsukamoto; Hajime Utsunomiya; Yoshiaki Yamanaka; Akihisa Hatakeyama; Shiho Kanezaki; Akinori Sakai
Journal:  Orthop J Sports Med       Date:  2021-11-01

8.  A descriptive prospective study of sports medicine practices for athletes in Uganda.

Authors:  Samuel K Lubega; Timothy Makubuya; Haruna Muwonge; Mike Lambert
Journal:  Afr Health Sci       Date:  2021-06       Impact factor: 0.927

9.  Periacetabular Osteotomy in United States Military Personnel: Results From an Interservice Hip Preservation Practice.

Authors:  Andrew S Murtha; Matthew R Schmitz
Journal:  Orthop J Sports Med       Date:  2022-02-15

10.  Does Daily Physical Activity Differ Between Patients with Femoroacetabular Impingement Syndrome and Patients with Hip Dysplasia? A Cross-Sectional Study in 157 Patients and 60 Healthy Volunteers.

Authors:  Lisa C U Reimer; Signe Kierkegaard; Inger Mechlenburg; Julie S Jacobsen
Journal:  Int J Sports Phys Ther       Date:  2021-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.